Cargando…
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
BACKGROUND: The epidermal growth factor receptor (EGFR)/RAS/RAF/MEK/MAPK pathway is an important pathway in the carcinogenesis, invasion and metastasis of colorectal cancers (CRCs). We conducted a retrospective study to determine the prognostic values of EGFR expression and KRAS mutation in patients...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878756/ https://www.ncbi.nlm.nih.gov/pubmed/24330663 http://dx.doi.org/10.1186/1471-2407-13-599 |
_version_ | 1782297860351459328 |
---|---|
author | Huang, Ching-Wen Tsai, Hsiang-Lin Chen, Yi-Ting Huang, Chun-Ming Ma, Cheng-Jen Lu, Chien-Yu Kuo, Chao-Hung Wu, Deng-Chyang Chai, Chee-Yin Wang, Jaw-Yuan |
author_facet | Huang, Ching-Wen Tsai, Hsiang-Lin Chen, Yi-Ting Huang, Chun-Ming Ma, Cheng-Jen Lu, Chien-Yu Kuo, Chao-Hung Wu, Deng-Chyang Chai, Chee-Yin Wang, Jaw-Yuan |
author_sort | Huang, Ching-Wen |
collection | PubMed |
description | BACKGROUND: The epidermal growth factor receptor (EGFR)/RAS/RAF/MEK/MAPK pathway is an important pathway in the carcinogenesis, invasion and metastasis of colorectal cancers (CRCs). We conducted a retrospective study to determine the prognostic values of EGFR expression and KRAS mutation in patients with metastatic CRC (mCRC) based on synchronous or metachronous status. METHODS: From October 2002 to March 2012, 205 patients with mCRC were retrospectively analyzed; 98 were found to have metachronous mCRC while 107 were found to have synchronous mCRC. The EGFR expressions were determinate by IHC (immunohistochemistry) analysis and categorized 1+ (weak intensity), 2+ (moderate intensity), and 3+ (strong intensity). Genomic DNA was isolated from frozen primary CRC tissues and direct sequencing of KRAS was performed. The clinicopathological features of these mCRC patients were retrospectively investigated according to EGFR expression and KRAS mutation status. Moreover, we analyzed the prognostic values of EGFR expression and KRAS mutation among these patients. RESULTS: Of the 205 patients with mCRC, EGFR expression was analyzed in 167 patients, and positive EGFR expression was noted in 140 of those patients (83.8%). KRAS mutation was investigated in 205 patients and mutations were noted in 88 of those patients (42.9%). In patients with metachronous mCRC, positive EGFR expression was significantly correlated with well-and moderately-differentiated tumors (P = 0.028), poorer disease-free survival (DFS) (P < 0.001), and overall survival (OS) (P < 0.001). Furthermore, positive EGFR expression was a significant independent prognostic factor of DFS (P = 0.006, HR: 4.012, 95% CI: 1.130–8.445) and OS (P = 0.028, HR: 3.090, 95% CI: 1.477–10.900) in metachronous mCRC patients. KRAS mutation status was not significantly related to DFS and OS of patients with metachronous mCRC; likewise, KRAS mutation status was not significantly different in the progression-free survival (PFS) and OS of patients with synchronous mCRC (all P > 0.05). CONCLUSIONS: The present study demonstrated that EGFR expression has prognostic value only for patients with metachronous mCRC. However, KRAS mutation did not have prognostic value in patients with metachronous or synchronous mCRC. |
format | Online Article Text |
id | pubmed-3878756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38787562014-01-03 The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer Huang, Ching-Wen Tsai, Hsiang-Lin Chen, Yi-Ting Huang, Chun-Ming Ma, Cheng-Jen Lu, Chien-Yu Kuo, Chao-Hung Wu, Deng-Chyang Chai, Chee-Yin Wang, Jaw-Yuan BMC Cancer Research Article BACKGROUND: The epidermal growth factor receptor (EGFR)/RAS/RAF/MEK/MAPK pathway is an important pathway in the carcinogenesis, invasion and metastasis of colorectal cancers (CRCs). We conducted a retrospective study to determine the prognostic values of EGFR expression and KRAS mutation in patients with metastatic CRC (mCRC) based on synchronous or metachronous status. METHODS: From October 2002 to March 2012, 205 patients with mCRC were retrospectively analyzed; 98 were found to have metachronous mCRC while 107 were found to have synchronous mCRC. The EGFR expressions were determinate by IHC (immunohistochemistry) analysis and categorized 1+ (weak intensity), 2+ (moderate intensity), and 3+ (strong intensity). Genomic DNA was isolated from frozen primary CRC tissues and direct sequencing of KRAS was performed. The clinicopathological features of these mCRC patients were retrospectively investigated according to EGFR expression and KRAS mutation status. Moreover, we analyzed the prognostic values of EGFR expression and KRAS mutation among these patients. RESULTS: Of the 205 patients with mCRC, EGFR expression was analyzed in 167 patients, and positive EGFR expression was noted in 140 of those patients (83.8%). KRAS mutation was investigated in 205 patients and mutations were noted in 88 of those patients (42.9%). In patients with metachronous mCRC, positive EGFR expression was significantly correlated with well-and moderately-differentiated tumors (P = 0.028), poorer disease-free survival (DFS) (P < 0.001), and overall survival (OS) (P < 0.001). Furthermore, positive EGFR expression was a significant independent prognostic factor of DFS (P = 0.006, HR: 4.012, 95% CI: 1.130–8.445) and OS (P = 0.028, HR: 3.090, 95% CI: 1.477–10.900) in metachronous mCRC patients. KRAS mutation status was not significantly related to DFS and OS of patients with metachronous mCRC; likewise, KRAS mutation status was not significantly different in the progression-free survival (PFS) and OS of patients with synchronous mCRC (all P > 0.05). CONCLUSIONS: The present study demonstrated that EGFR expression has prognostic value only for patients with metachronous mCRC. However, KRAS mutation did not have prognostic value in patients with metachronous or synchronous mCRC. BioMed Central 2013-12-13 /pmc/articles/PMC3878756/ /pubmed/24330663 http://dx.doi.org/10.1186/1471-2407-13-599 Text en Copyright © 2013 Huang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Huang, Ching-Wen Tsai, Hsiang-Lin Chen, Yi-Ting Huang, Chun-Ming Ma, Cheng-Jen Lu, Chien-Yu Kuo, Chao-Hung Wu, Deng-Chyang Chai, Chee-Yin Wang, Jaw-Yuan The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer |
title | The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer |
title_full | The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer |
title_fullStr | The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer |
title_full_unstemmed | The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer |
title_short | The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer |
title_sort | prognostic values of egfr expression and kras mutation in patients with synchronous or metachronous metastatic colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878756/ https://www.ncbi.nlm.nih.gov/pubmed/24330663 http://dx.doi.org/10.1186/1471-2407-13-599 |
work_keys_str_mv | AT huangchingwen theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT tsaihsianglin theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT chenyiting theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT huangchunming theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT machengjen theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT luchienyu theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT kuochaohung theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT wudengchyang theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT chaicheeyin theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT wangjawyuan theprognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT huangchingwen prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT tsaihsianglin prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT chenyiting prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT huangchunming prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT machengjen prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT luchienyu prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT kuochaohung prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT wudengchyang prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT chaicheeyin prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer AT wangjawyuan prognosticvaluesofegfrexpressionandkrasmutationinpatientswithsynchronousormetachronousmetastaticcolorectalcancer |